Загрузка...
Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
BACKGROUND: The effectiveness of atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer (TNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on advanced TNBC from the US payer perspective. METHODS: A Markov model was adopted to project the disease course of...
Сохранить в:
| Опубликовано в: : | Ther Adv Med Oncol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222249/ https://ncbi.nlm.nih.gov/pubmed/32426048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920916000 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|